Disease burden, symptoms, and use of analgesics in patients with psoriasis with or without psoriatic arthritis: A cross-sectional study
Research output: Contribution to journal › Journal article › Research › peer-review
Documents
- Fulltext
Final published version, 1.01 MB, PDF document
Background: Patients with psoriasis have an impaired quality of life and higher use of analgesics than the general population. Whether such use is due to skin pain or a consequence of joint pain resulting from psoriatic arthritis (PsA) is not clear. Objectives: To assess symptoms, disease burden, and use of analgesics in patients with psoriasis with and without PsA. Method: Symptoms, general health (EurQol 5-dimension and 5-levels), and use of analgesics were assessed in patients with psoriasis and the general population from the Danish Skin Cohort. Results: We included 4016 patients with psoriasis (847 with concomitant PsA) and 3490 reference individuals. For patients with psoriasis having PsA, itch, skin pain, and/or joint pain was associated with worse general health. Use of opioids within 12 months was observed among 9.0% of the general population, 14.2% of patients with psoriasis without PsA, and 22.7% of patients with concomitant PsA. Of the symptoms, only joint pain was associated with use of analgesics (odds ratio, 3.72 (2.69-5.14); P < .0001). Limitations: Cross-sectional design. Conclusion: Patients with psoriasis (especially concomitant PsA) have a higher use of analgesics compared with the general population, which appears to be a result of increased joint pain.
| Original language | English |
|---|---|
| Journal | Journal of the American Academy of Dermatology |
| Volume | 86 |
| Issue number | 3 |
| Pages (from-to) | 590-597 |
| Number of pages | 8 |
| ISSN | 0190-9622 |
| DOIs | |
| Publication status | Published - Mar 2022 |
Bibliographical note
Funding Information:
Dr Loft has been an honorary speaker for Eli Lilly and Janssen Cilag. Dr. Nguyen reports no potential conflicts of interest. Dr Kristensen has received fees for as a speaker and consultant for Pfizer, AbbVie, Amgen, Forward pharma, UCB, Gilead, Biogen, BMS, MSD, Novartis, Eli Lilly, and Janssen Pharmaceuticals. Dr Thyssen reports no relevant conflicts of interest. Dr Egeberg has received research funding from Pfizer, Eli Lilly , Novartis, AbbVie, Janssen Pharmaceuticals, the Danish National Psoriasis Foundation , the Simon Spies Foundation, and the Kgl Hofbundtmager Aage Bang Foundation , and honoraria as consultant and/or speaker from AbbVie, Almirall, Leo Pharma, Sun Pharmaceuticals, Galapagos NV, Samsung Bioepis Co, Ltd., Pfizer, Eli Lilly and Company, Novartis, Galderma, Dermavant, UCB, Mylan, Bristol-Myers Squibb, and Janssen Pharmaceuticals.
Funding Information:
Dr Loft has been an honorary speaker for Eli Lilly and Janssen Cilag. Dr. Nguyen reports no potential conflicts of interest. Dr Kristensen has received fees for as a speaker and consultant for Pfizer, AbbVie, Amgen, Forward pharma, UCB, Gilead, Biogen, BMS, MSD, Novartis, Eli Lilly, and Janssen Pharmaceuticals. Dr Thyssen reports no relevant conflicts of interest. Dr Egeberg has received research funding from Pfizer, Eli Lilly, Novartis, AbbVie, Janssen Pharmaceuticals, the Danish National Psoriasis Foundation, the Simon Spies Foundation, and the Kgl Hofbundtmager Aage Bang Foundation, and honoraria as consultant and/or speaker from AbbVie, Almirall, Leo Pharma, Sun Pharmaceuticals, Galapagos NV, Samsung Bioepis Co, Ltd., Pfizer, Eli Lilly and Company, Novartis, Galderma, Dermavant, UCB, Mylan, Bristol-Myers Squibb, and Janssen Pharmaceuticals. Funding sources: None.
Publisher Copyright:
© 2021 American Academy of Dermatology, Inc.
- analgesics, itch, opioids, pain, patient-reported outcomes, psoriasis, psoriatic arthritis, quality of life
Research areas
ID: 314145620